Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple supplement turn back the clock on aging?

NCT ID NCT07114536

Disease control Sponsor: Shenzhen Hygieia Biotech Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 17, 2026 · Updated 4 times

Summary

This study tests whether a dietary supplement called calcium alpha-ketoglutarate (CaAKG) can slow biological aging and improve physical performance and metabolic health in adults aged 40 to 75. Thirty participants will take either CaAKG or a placebo daily for 12 weeks. Researchers will measure changes in biological age using a blood-based test called PhenoAge, along with other health markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
calcium alpha-ketoglutarate (CaAKG) dietary supplement
What this could lead to
If it works, this could point toward a simple dietary supplement that helps slow biological aging and improve physical health in middle-aged and older adults.
What could go wrong
This is a very small early trial with only 30 participants, so results may not apply to everyone. The supplement may have no effect on aging or could cause side effects not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

34 people

The number who actually took part.

Started

Aug 2025

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 40-75 years old, no gender restrictions. 2. Has not taken any other anti-ageing research products in the past two months. 3. Able to use a smartphone. 4. Informed consent, voluntarily signed informed consent form, and agreed to participate in all visits and treatments in accordance with the trial protocol. Exclusion Criteria: 1. Patients with cardiovascular disease, severe/uncontrolled hypertension, rheumatic heart disease, congenital heart disease, deep vein thrombosis, or pulmonary embolism . 2. Patients with Type I/Type II diabetes (treated with oral metformin or insulin) or diabetes complications . 3. Patients with cancer or who have undergone surgery, systemic drug therapy, or radiation therapy within the past 3 years. 4. Chronic obstructive pulmonary disease (COPD), severe asthma (requiring daily medication). 5. Multiple sclerosis, autoimmune/immunodeficiency disorders. 6. Recent history of sepsis or infection (hospitalisation within the past 3 months). 7. Any mental illness or neurodegenerative disease. 8. Any metallic implants in the body. 9. Hepatitis/cirrhosis. 10. Severe kidney disease (GFR \<30 mL/min/1.73 m²). 11. Suffering from other conditions deemed unsuitable for participation in this trial (as determined by the investigator).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aging

Contacts and locations

Locations

  • Zhejiang Chinese Medicine University

    Hangzhou, Zhejiang, 310051, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.